News for Annexon, Inc. (ANNX)

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Annexon Inc. (NASDAQ:ANNX) stands against other stocks that fall behind amid market optimism. Wall Street’s main indices rebounded from hefty losses on Wednesday after President Donald Trump announced that the […]

BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ( ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel ther

Annexon's ANX005 shows promise for Guillain-Barre treatment with strong phase 3 results. Click here to read an analysis of ANNX stock now.

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 202

BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ( ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel thera

BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ( ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel thera

**media[539930]**

On December 31, 2024, Vanguard Group Inc executed a significant transaction by acquiring an additional 576,625 shares of Annexon Inc at a price of $5.13 per sha

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWI

Annexon's Q3 2024 earnings release and 10-Q reveal mixed prospects, impacting investor confidence. Read why I rate ANNX stock as a Hold.

BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ( ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel thera

**media[493931]**

Annexon shares rise on positive Guillain-Barré study results

**media[484319]**

Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fove

On December 2, 2024, William Carson, a Director at Annexon Inc (ANNX), purchased 3,200 shares of the company. Following this transaction, the insider now owns a

**media[467664]**

Robust Growth in the Geographic Atrophy Market Driven by Aging Population and Technological Advances...

The next-generation complement therapeutics market is experiencing positive growth driven by the rising global incidence of cardiovascular, genetic,...